Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-Class Lupus Treatment ...Middle East

PR Newswire - News
Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-Class Lupus Treatment
COPENHAGEN, Denmark and NEW YORK, June 1, 2022 /PRNewswire/ --The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment...

Hence then, the article about lupus research alliance and lupus therapeutics response to positive data from phase 2 study on potential first in class lupus treatment was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-Class Lupus Treatment )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News